AYTU

AYTU is a $21M-market-cap specialty pharma whose own 10-K flags that its ability to continue as a going concern depends on 'continued operational improvements, refinancing, or obtaining adequate capital' — it carries a $333.5M accumulated deficit and has lost money every year since inception. The commercial base is stagnant and lower-quality than it looks: revenue is essentially flat at $66.4M (+1.8%) after collapsing from a $107M peak in FY2023, gross profit actually fell 6.6%, and operating income swung to -$7.83M (a 392% deterioration). The balance sheet is stretched, with liabilities/equity at 5.12x and stockholders' equity down 31.6% to just $19.0M. Net loss narrowed modestly to -$13.6M and operating cash burn is small (-$1.94M), but that is the best that can be said.

The bull case rests entirely on EXXUA (gepirone), the in-licensed first-in-class 5HT1a agonist for MDD that management calls a 'major growth catalyst' and planned to launch in Q4 CY2025 into a '$22 billion' market. That is a genuine option, but it is an unproven, pre-launch, execution-dependent bet in a market saturated with cheap generic antidepressants — precisely the kind of 'unknowable risk' that argues for staying out rather than underwriting.